Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore.
2026-07-31 17:30
•Matthew Benjamin •The Motley Fool
•• •• Axe Cap view
Why Eli Lilly Surges While Novo Nordisk Falters in Obesity Drugs
Eli Lilly’s dominant market share drives stock gains, while Novo Nordisk's new pill faces an uphill battle.
The global obesity drug market is booming, and Eli Lilly has taken commanding control with a 60% slice, helping its stock rally 58% over the past year. Novo Nordisk, despite pioneering GLP-1 drugs, has seen its share price crater by 62% since July. Investors seem to doubt Novo’s new pill-form drug Wegovy will recapture lost ground quickly. For South African investors, this story is less about picking local stocks and more about watching USD/ZAR, which may move with shifts in global pharma sentiment and risk appetite. A stronger dollar often pressures the rand, affecting JSE large caps reliant on imports or global supply chains like Aspen or Adcock Ingram. If Novo’s pill gains traction faster than expected, global risk appetite could improve, giving the rand some relief. But Lilly’s lead feels robust for now. If you want local exposure, hold steady with the rand and cautiously watch pharma-linked JSE stocks rather than jump in. this is just our opinion and not financial advice
Watch USD/ZAR for global risk shifts tied to pharma innovation. Avoid direct bets on local pharma stocks for now, as the competitive landscape remains unsettled.
- USD/ZAR
- Aspen Pharmacare
- Novo Nordisk’s pill gains faster adoption than expected
- Rand strengthens independent of global pharma moves due to local factors
6/10
Eli Lilly has significantly outperformed Novo Nordisk in the booming GLP-1 obesity drug market, with Lilly commanding 60% market share compared to Novo's smaller portion of the combined 87% duopoly. While the obesity drug market is projected to grow from $66 billion in 2025 to $120 billion by 2030, Lilly's stock has surged 58% over 52 weeks, whereas Novo has plummeted 62% since July 2024. However, Novo's recent launch of a pill-form obesity drug could shift the competitive landscape.
Our take is based on reporting first published by The Motley Fool.